PMS2 expression decrease causes severe problems in mismatch repair by Kasela, Mariann et al.
 This article has been accepted for publication and undergone full peer review but has 
not been through the copyediting, typesetting, pagination and proofreading process, 
which may lead to differences between this version and the Version of Record. Please 
cite this article as doi: 10.1002/humu.23756. 
 
This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
 
Mariann Kasela    ORCID iD: 0000-0001-9969-4361 
PMS2 expression decrease causes severe problems in 
mismatch repair 
Mariann Kasela, Minna Nyström, Minttu Kansikas* 
Molecular and Integrative Biosciences Research Programme, Faculty of Biological 
and Environmental Sciences, University of Helsinki, Helsinki, Finland 
*Correspondence 
Dr. Minttu Kansikas, PhD 
P.O Box 56 (Viikinkaari 9) 
FI-00014 Helsinki, Finland.  
E-mail:minttu.kansikas@helsinki.fi 
Contract grant sponsors: Jane and Aatos Erkko Foundation  
Abstract 
PMS2 is one of the four susceptibility genes in Lynch syndrome (LS), the most 
common cancer syndrome in the world. Inherited mutations in DNA mismatch repair 
(MMR) genes, MLH1, MSH2, and MSH6, account for approximately 90% of LS, 
while a relatively small number of LS families segregate a PMS2 mutation. This and 
the low cancer penetrance in PMS2 families suggest that PMS2 is only a moderate or 
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low risk susceptibility gene. We have previously shown that even a partial expression 
decrease in MLH1, MSH2 or MSH6 suggests that heterozygous LS mutation carriers 
have MMR malfunction in constitutive tissues. Whether and how PMS2 expression 
decrease affects the repair capability is not known. Here, we show that PMS2 
knockdown cells retaining 19%, 33% or 53% of PMS2 expression all have 
significantly reduced MMR efficiency. Surprisingly, the cells retaining expression 
levels comparable to PMS2 mutation carriers indicate the lowest repair efficiency.  
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As a component of the MutLα (MLH1+PMS2) heterodimer, PMS2 
(postmeiotic segregation increased 2) is central in the post-replicative human DNA 
mismatch repair (MMR) mechanism (Kunkel & Erie, 2005). Heterozygous germline 
mutations in MMR genes cause Lynch syndrome (LS; MIM# 120435), the most 
common cancer predisposition syndrome in human (de la Chapelle, 2004; Lynch, 
Snyder, Shaw, Heinen, & Hitchins, 2015). Mutations in MLH1 (MIM# 120436) and 
MSH2 (MIM# 609309) are the most prevalent in known LS families (36.2% and 
35.3%, respectively), while the number of MSH6 (MIM# 600678) and PMS2 (MIM# 
600259) mutations is lower (19.4% and 9.1%, respectively) (www.insight-
database.org, data accessed 22.01.2019). The absence of functional MMR protein 
results in DNA repair malfunction, which is the cause of early onset colorectal and 
endometrial cancers and less frequently cancer of the ovaries, stomach, pancreas, 
prostate and breast in LS families (Lynch et al., 2015). However, in PMS2 families the 
prevalence of stomach, prostate and breast cancers is unusually high and compared to 
MLH1 and MSH2 families, also the mean age of cancer onset is higher and the 
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penetrance of colorectal and endometrial cancers lower, resembling the situation in 
MSH6 families (Hendriks et al., 2006; Roberts et al., 2018; Senter et al., 2008; ten 
Broeke et al., 2015; Truninger et al., 2005). One explanation for the lower cancer 
penetrance in PMS2 families might be the protein homologue MLH3, which is also 
able to bind and partially function with MLH1 (Cannavo et al., 2005; Korhonen, 
Raevaara, Lohi, & Nystrom, 2007; Senter et al., 2008; ten Broeke et al., 2015).  
The diagnostic workflow to identify Lynch syndrome typically involves tumor 
studies and DNA analyses. The first clinical step in diagnosing LS includes tumor 
immunohistochemistry (IHC) and microsatellite instability (MSI) analyses followed 
by mutation screening dictated by the IHC and MSI results (Kansikas, Kariola, & 
Nystrom, 2011; Yurgelun & Hampel, 2018). While IHC is a valuable method for 
distinguishing PMS2 carriers, who generally lose only PMS2, from MLH1 carriers, 
who frequently lose both MLH1 and PMS2 protein expressions in a tumor (Niessen et 
al., 2009), it took a decade to differentiate sequence between PMS2 and its 15 
pseudogenes for reliable sequencing and mutation detection (De Vos, Hayward, 
Picton, Sheridan, & Bonthron, 2004; van der Klift et al., 2010; Vaughn et al., 2010). 
As an outcome, the prevalence of PMS2 mutations in suspected LS families has 
increased according to the InSiGHT database, from approximately 2% to 9% during 
the last two decades (www.insight-database.org). Furthermore, the population-based 
PMS2 variant prevalence was recently reported to be relatively high (1:714) compared 
to the variant prevalence in MLH1 (1:1946) and MSH2 (1:2841) (Win et al., 2017) and 
a strikingly high prevalence (96%) was reported from an Icelandic population using 
whole genome sequencing data of a colorectal cancer cohort (Haraldsdottir et al., 
2017).  
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Nevertheless, atypical clinical phenotypes and a low cancer penetrance in 
PMS2 families still question its role in Lynch syndrome. Hence, this study aimed to 
determine the significance of PMS2 as an LS susceptibility gene by analyzing whether 
a partial PMS2 expression decrease, comparable to the expression decrease in a Lynch 
syndrome mutation carrier, causes mismatch repair malfunction, as was previously 
shown to be the case with the susceptibility genes MLH1, MSH2 and MSH6. 
Accordingly, stable shRNA mediated PMS2 knockdown (KD) clones were 
established and characterized by real-time PCR (RT-Q-PCR), and the clones with 
reduced PMS2 expression were included in functional MMR analyses (Supporting 
Materials, Materials & Methods). Each KD clone had its own specific control across 
all studies to avoid experimental artefacts. A prerequisite for the functional analysis 
was that the PMS2 mRNA expression level should be at most ~50% of the normal 
level, a level comparable to that of an LS mutation carrier. From a total of 16 clones, 
the three retaining 19%, 33% and 53% of PMS2 mRNA expression met the criteria for 
further MMR analysis.  
In order to be able to assess the repair efficiency of each clone, the nuclear 
proteins of the cells in chosen clones and their controls were extracted in parallel as 
described previously (Holmes, Clark, & Modrich, 1990; Kantelinen et al., 2010). The 
nuclear protein expression was analyzed by Western blot (WB) (Supporting Materials, 
Materials & Methods) (Figure 1). Despite the semi-quantitative nature of the method, 
each KD clone clearly showed decreased PMS2 protein expression compared to the 
level in its respective control (NC), indicating that the amount of protein reflects the 
reduced mRNA expression in the cell extract. Importantly, the MLH1 protein 
expression was shown to be normal in the KD extracts.  
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For a long time, PMS2 mutation prevalence was underestimated, suggesting 
that PMS2 is not an important LS susceptibility gene. Its significance in LS has been 
questioned by the atypically low cancer penetrance in PMS2 families (Senter et al., 
2008; ten Broeke et al., 2015), an unclear risk for extra-colonic cancers (Roberts et al., 
2018; Ten Broeke et al., 2018), as well as inconsistencies across studies due to 
variable cohort sizes and carrier ascertainment (compliant with Amsterdam II criteria 
and/or revised Bethesda Guidelines) (Senter et al., 2008; ten Broeke et al., 2015; Ten 
Broeke, Suerink, & Nielsen, 2018; Ten Broeke et al., 2018). For these reasons, PMS2-
specific surveillance methods remain under debate (Espenschied et al., 2017; Ten 
Broeke et al., 2018).  
Nevertheless, over 20% of PMS2 carriers are still estimated to be missed with 
the conventional criteria used for LS identification (Senter et al., 2008; ten Broeke et 
al., 2015). The IHC- and MSI- studies help the pathogenicity assessment since up to 
99% of PMS2 carriers have been shown to lack PMS2 in tumor tissue, and 98% of 
tumors have been characterized as MSI-high (Goodenberger et al., 2016). Since both 
these tumor phenotypes signal MMR deficiency, it was anticipated that PMS2 
expression decrease should also interfere with MMR capability of the cells, as was 
previously shown to be the case with the other LS susceptibility genes (Kansikas, 
Kasela, Kantelinen, & Nystrom, 2014). Indeed, the functional in vitro MMR assay 
(Nystrom-Lahti et al., 2002; Raevaara et al., 2003) (Supporting Materials, Materials & 
Methods) demonstrated lowered MMR efficiency in cells with reduced PMS2 mRNA 
expression, while all controls maintained higher repair proficiencies throughout three 
independent assays (Figure 2a). The reduction in MMR capability in cells retaining 
19%, 33% or 53% of PMS2 mRNA expression was statistically significant (according 
to Student’s T-Test) in all, showing 21%, 15% and 12% of average repair efficiency, 
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while their controls showed 38%, 55% and 48% of repair capability, respectively (p = 
0.002, 0.001, and 0.0002) (Figure 2a). Interestingly, the most severe repair defect was 
in cells retaining 53% of PMS2 expression. The relative repair efficiencies (RR%) of 
cells retaining 19%, 33% and 53% of PMS2 mRNA expression were 55%, 27% and 
25%, respectively (Figure 2b), confirming the finding that the KD cells with 53% 
PMS2 expression had the lowest repair capability.  
Previously, a significant reduction in MMR efficiency was detected in cells 
retaining 75% of MSH6, 50% of MSH2, and 25% of MLH1 mRNA expression 
(Kansikas et al., 2014). In this study, we show that PMS2 expression decrease also 
affects MMR capability but unexpectedly in a different way than what was observed 
with the other MMR genes. Surprisingly, the lower PMS2 expression levels (19% and 
33%) had higher repair efficiencies than the carrier-like level (53%), while in MLH1 
and MSH2, 25% expression level was not enough to maintain any repair capability 
(25% level in MSH6 was not studied) (Kansikas et al., 2014). The severity of MLH1 
and MSH2 expression decrease may be due to their obligatory roles in the 
heterodimeric protein complexes (Acharya et al., 1996; Kondo, Horii, & Fukushige, 
2001), while such a low level of PMS2 may be compensated by some homologous 
protein. Compensation of MutLα with MutLγ (MLH1+MLH3) has been suggested to 
explain the low penetrance of PMS2 mutations (Cannavo et al., 2005; Korhonen et al., 
2007). Although PMS2 is the main partner of MLH1 among MutL homologues, 
MutLγ has shown at least low MMR capability (Cannavo et al., 2005; Raschle, Marra, 
Nystrom-Lahti, Schar, & Jiricny, 1999). The nuclear localization of MLH3 seems to 
be dependent on the absence of PMS2 in the cell (Korhonen et al., 2007), and while 
excess of MLH3 has been shown to reduce PMS2 binding to MLH1, most probably 
MLH3 is not a significant counterpart to MLH1 in a normal cell due to the 60-fold 
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higher expression of PMS2 (Cannavo et al., 2005; Kondo et al., 2001). To determine 
whether MLH3 could compensate MMR efficiency in 19% and 33% PMS2 KD clones 
and improve their repair capability compared to the 53% clone, we further studied 
MLH3 mRNA expression and protein expression in the clones. Although, the MLH3 
mRNA expression levels were decreased, they did not differ between the KD cells 
(Supporting Materials, Supp. Figure S1), even though slightly lowered MLH3 protein 
expression in 53% KD clone compared to 19% clone was detected by WB 
(Supporting Materials, Supp. Figure S2). While MLH3 expression differences do not 
explain the lowered MMR efficiency in KD clones, it is still possible that the cells 
expressing only 19% or 33% of PMS2 are able to activate a “survival mechanism” 
that sustains MMR capability. 
By using a functional approach to assess the significance of PMS2 in Lynch 
syndrome, we show that PMS2 expression decrease causes severe problems in 
mismatch repair, which is the hallmark of LS susceptibility genes.  
Disclosure statement: Nyström and Kansikas are inventors on patent number 
PCT/EP2012/062708. Nyström is a shareholder and a board member and Kansikas 
and Kasela are employees of LS CancerDiag Ltd. 
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Figures 
Figure 1. Western blot analysis of KD extracts with reduced PMS2 mRNA 
expression 
Western Blot analysis was used to evaluate PMS2 protein expression of KD extracts 
and their controls. Commercial HCT116 cell line (ATCC® CCL-247™) lacks both 
MLH1 and PMS2 protein and served as a negative control, α-tubulin was used as a 
loading control. The results demonstrated decreased PMS2 protein expression in KD 
extracts, while the amount of MLH1 remained normal. Moreover, PMS2 protein 
expression increased according to mRNA expression in the clones.  
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Figure 2. Functional MMR efficiency of KD extracts with reduced PMS2 mRNA 
expression 
a. In order to investigate the effects of reduced PMS2 mRNA expression on the MMR 
capability, nuclear proteins extracted from KD cells were analyzed in the functional 
MMR assay. The average of absolute repair efficiencies (AR% n=3) of KD extracts and 
their controls were calculated from three repetitions and are illustrated below the gel 
electrophoresis picture. A significant decrease in the MMR efficiency was observed in 
all extracts retaining 19%, 33% or 53% of PMS2 mRNA expression compared to their 
respective controls (p= 0.002; 0.001; 0.0002, respectively).  
b. Relative repair efficiencies (RR%) were calculated from the AR% values of the KD 
extracts relative to the AR% values of their respective controls (set to 100). These 
results further confirm the finding that the cells with 53% PMS2 expression have the 
lowest repair capability.  
 
